Wednesday, August 26, 2026

Capital Markets & M&A

2 articles

TPG Raises $51 Billion in 2025 as Private Equity Firms Pivot to Credit and Alternative Strategies

TPG Raises $51 Billion in 2025 as Private Equity Firms Pivot to Credit and Alternative Strategies

TPG raised $51 billion in 2025, up from $30 billion the previous year, while cutting private equity concentration from 80% to 40% of AUM since its IPO. The shift reflects broader industry diversification into credit markets, with Third Point launching new private credit funds and Ancient Financial Holdings acquiring F&G Life Re as alternative asset managers chase growth beyond traditional buyouts.

ViaNews Editorial Team (Markets)
Nvidia Backs $1.17B AI Infrastructure Deal as SoftBank-Marvell Realignment Signals Chip Sector Consolidation

Nvidia Backs $1.17B AI Infrastructure Deal as SoftBank-Marvell Realignment Signals Chip Sector Consolidation

Nvidia committed $1.17B to AI infrastructure investments while SoftBank pursues strategic realignment with Marvell, marking institutional capital flows into semiconductor supply chains. Rezolve Ai reported 650+ enterprise clients processing billions of API calls, demonstrating commercial-scale generative AI deployment. The moves reflect investor confidence in sustained AI demand despite organic search traffic declining up to 50% as AI-powered search replaces conventional SEO.

ViaNews Editorial Team (Markets)
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com